Yesterday, the UK government released it Life Sciences Sector Plan (LSSP). The British government introduced the provisions in this way:
1. Unlock NHS data to find new treatment. Investment of £ 600 million for the creation of the world’s most advanced health data system – helps scientists to develop better treatment.
2. IntensityCutting red tape so that patients can soon join the tests-and get access to life-changing medicines quickly.
3. Supporting British manufacturing. To invest in life science building projects £ 520 million-up-high-skilled jobs and make more treatment and medical equipment here at home.
4. Getting patients rapidly getting new treatment. Making regulation simple and sharp by increasing departmental support MHRA With additional investment – so doctors can use safe, effective innovations without delay.
5. Helping doctors to use state -of -the -art technology. To roll out the devices that prove a new NHS ‘passport’ – like Aye Cancer scanner or wearable equipment that quickly detect the disease.
6. Supporting fantastic UK firms to grow. Rapid growing companies increase investment, helping to stay in scale up and UK-at least one year is a major industry partnership.
What was the reaction from the field of life science? The association of the British Pharmaceutical Industry (ABPI) was overwhelmed.
The government’s new scheme includes many important and necessary commitments to support the use of data for research, encourage investment in manufacturing and accelerate the pace and ease of research. While these are positive, they are not sufficient to reverse the decline of Britain standing as a life science center.
ABPI Chief Executive, Richard Turbate said: “The scheme recognizes both the extraordinary contribution of the field of life science in the UK, and the fact that in recent years, it is struggling to remain competitive and attractive for investment. The proposed solutions are essential and important, but they are not sufficient to move around the UK decline.
“The UK must address the main issue to keep the life science field back, long -term disinvestment in new drugs that NHS is preventing patients from reaching drugs available in other countries.
“For a very long time, the UK has sought the place where innovation occurs, but not the place where it is used. Without change, the UK will continue slide slides for the International League table for research, investment and availability of new drugs.
The NHS Confederation, an organization supporting the healthcare systems in England, Wales and Northern Ireland, argues that innovation alone is not enough, but also reach and value.
While the LSSP determines how the government strives to increase the amount and quality of industrial science in the UK, its tangible effect will be limited if patients cannot get rapid access to the most clinical and costly new techniques developed as part of these efforts and if not supported to transport health leaders on the plan.
What do you think on LSSP?
